Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid basal cell carcinoma

British Journal of Ophthalmology

Volumn 95, Issue 10, 2011, Pages 1393-1396

  Garcia Martin, Elena ^a,b   Gil Arribas, L M ^a,b   Idoipe, M ^a   Alfaro, J ^a   Pueyo, V ^a,b   Pablo, L E ^a,b   Fernandez, F J ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; IMIQUIMOD; TOBRAMYCIN;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CREAM; DRUG EFFICACY; DRUG TOLERABILITY; DRY EYE; EYE DISCOMFORT; EYE IRRITATION; EYELID CARCINOMA; EYELID PAIN; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HISTOPATHOLOGY; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; THERAPY EFFECT;

AGED; AGED, 80 AND OVER; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; EYELID NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 80053235019     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2010.193078     Document Type: Article

References (25)

1. Allali J, D'Hermies F, Renard G. Basal cell carcinomas of the eyelids. Ophthalmologica 2005;219:57-71. (Pubitemid 40529281)
2. Christenson LJ, Borrowman TA, Vachon CM, et al. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA 2005;294:681-90. (Pubitemid 41159287)
3. Kakudo N, Ogawa Y, Suzuki K, et al. Clinical outcome of surgical treatment for periorbital basal cell carcinoma. Ann Plast Surg 2009;63:531-5.
4. Silverman MK, Kopf AW, Grin CM, et al. Recurrence rates of treated basal cell carcinomas. Part 2: Curettage-electrodesiccation. J Dermatol Surg Oncol 1991;17:720-6.
5. Drake LA, Ceilley RI, Cornelison RL, et al. Guidelines of care for basal cell carcinoma. The American Academy of Dermatology Committee on Guidelines of Care. J Am Acad Dermatol 1992;26:117-20.
6. Fleming ID, Amonette R, Monaghan T, et al. Principles of management of basal and squamous cell carcinoma of the skin. Cancer 1995;75:699-704.
7. Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989;15:315-28. (Pubitemid 19085793)
8. Goldberg LH. Basal cell carcinoma. Lancet 1996;347:663-7. (Pubitemid 26076136)
9. Bath-Hextall FJ, Perkins W, Bong J, et al. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev 2007;(1):CD003412.
10. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002;3:196-200. (Pubitemid 34141451)
11. Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004;50:722-33. (Pubitemid 38580549)
12. Peris K, Campione E, Micantonio T, et al. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial. Dermatol Surg 2005;31:318-23. (Pubitemid 43072987)
13. Schiessl C, Wolber C, Tauber M, et al. Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up. J Drugs Dermatol 2007;6:507-13.
14. Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol 2009;145:1431-8.
15. Berman B. Scientific rationale: combining imiquimod and surgical treatments for basal cell carcinomas. J Drugs Dermatol 2008;7:s3-6.
16. Vidal D, Matias-Guiu X, Alomar A. Fifty-five basal cell carcinomas treated with topical imiquimod: outcome at 5-year follow-up. Arch Dermatol 2007;143:266-8. (Pubitemid 46294599)
17. Huber A, Huber JD, Skinner RB Jr, et al. Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series. Dermatol Surg 2004;30:429-30. (Pubitemid 38524166)
18. Beutner KR, Geisse JK, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999;41:1002-7.
19. Shumack S, Robinson J, Kossard S, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol 2002;138:1165-71. (Pubitemid 35025688)
20. Rigel DS, Torres AM, Ely H. Imiquimod 5% cream following curettage without electrodesiccation for basal cell carcinoma: preliminary report. J Drugs Dermatol 2008;7:s15-16.
21. Swanson EL, Amdur RJ, Mendenhall WM, et al. Radiotherapy for basal cell carcinoma of the medial canthus region. Laryngoscope 2009;119:2366-8.
22. Carneiro RC, De Macedo EM, Matayoshi S. Imiquimod 5% cream for the treatment of periocular basal cell carcinoma. Ophthal Plast Reconstr Surg 2010;26:100-2.
23. Choontanom R, Thanos S, Busse H, et al. Treatment of basal cell carcinoma of the eyelids with 5% topical imiquimod: a 3-year follow-up study. Graefes Arch Clin Exp Ophthalmol 2007;245:1217-20. (Pubitemid 47034345)
24. Leppälä J, Kaarniranta K, Uusitalo H, et al. Imiquimod in the treatment of eyelid basal cell carcinoma. Acta Ophthalmol Scand 2007;85:566-8. (Pubitemid 47163120)
25. Blasi MA, Giammaria D, Balestrazzi E. Immunotherapy with imiquimod 5% for eyelid nodular basal cell carcinoma. Am J Ophthalmol 2005;140:1136-9. (Pubitemid 41821311)